The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of irinotecan and temsirolimus in patients with refractory sarcomas.
S. Movva
No relevant relationships to disclose
T. Bocklage
No relevant relationships to disclose
B. Schmit
No relevant relationships to disclose
R. Quinn
No relevant relationships to disclose
B. J. Liem
No relevant relationships to disclose
C. F. Verschraegen
No relevant relationships to disclose